Genmab A/S (NASDAQ:GMAB) Stake Lifted by Gallacher Capital Management LLC

Gallacher Capital Management LLC increased its stake in shares of Genmab A/S (NASDAQ:GMAB) by 17.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,865 shares of the company’s stock after buying an additional 1,192 shares during the quarter. Gallacher Capital Management LLC’s holdings in Genmab A/S were worth $235,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in GMAB. Pinnacle Bancorp Inc. boosted its position in Genmab A/S by 315.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after acquiring an additional 638 shares during the period. GAMMA Investing LLC boosted its position in Genmab A/S by 194.0% during the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after acquiring an additional 749 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Genmab A/S during the 1st quarter worth $43,000. Principal Securities Inc. acquired a new position in Genmab A/S during the 4th quarter worth $77,000. Finally, Advisors Preferred LLC acquired a new position in Genmab A/S during the 4th quarter worth $82,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on GMAB shares. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, June 27th. Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. BTIG Research upped their price objective on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Finally, Truist Financial upped their price objective on Genmab A/S from $50.00 to $53.00 and gave the company a “buy” rating in a report on Tuesday, June 4th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $49.50.

Genmab A/S Stock Up 2.8 %

Shares of NASDAQ GMAB traded up $0.73 during mid-day trading on Friday, hitting $26.97. 218,126 shares of the company traded hands, compared to its average volume of 554,367. Genmab A/S has a 1 year low of $24.53 and a 1 year high of $42.72. The stock has a market capitalization of $17.84 billion, a price-to-earnings ratio of 21.87, a PEG ratio of 0.94 and a beta of 0.97. The business has a 50 day moving average of $27.44 and a two-hundred day moving average of $28.76.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, May 2nd. The company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The business had revenue of $603.30 million during the quarter, compared to the consensus estimate of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. As a group, research analysts anticipate that Genmab A/S will post 1.11 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.